Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd's product candidate, eftilagimod alfa (efti), has demonstrated significant efficacy in enhancing overall response rates (ORR) in less responsive patient populations, achieving a 22.2% increase over historical treatment rates when combined with standard of care (SOC) in non-small cell lung cancer (1L NSCLC). The company's robust patent portfolio and the versatility of efti to complement existing PD-(L)1 therapies create substantial opportunities for expanding its market footprint and developing new treatment franchises. Additionally, the clinical successes in driving more conversions to partial and complete responses (PRs and CRs) highlight the potential for efti to become a transformative therapy in immuno-oncology.

Immutep Ltd's stock faces a negative outlook primarily due to underwhelming clinical results for its lead product candidate, eftilagimod alfa (efti), which has led to a reduced probability of success in non-small cell lung cancer (NSCLC) to just 30%. Furthermore, the findings from the INSIGHT-003 trial indicate significantly lower efficacy outcomes, particularly with increased representation of patients with lower tumor proportions, suggesting that overall results will likely fall short of historical benchmarks. Additionally, LAG-3 antagonists, such as Immutep's offerings, have shown inconsistent results in lung cancer treatments and are not generally regarded as transformative within the clinical landscape, creating a perceptual barrier to acceptance in the market.